We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
+11.45%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$76M
AUM Growth
-$11.1M
(-13%)
Cap. Flow
+$112M
Cap. Flow
% of AUM
147.28%
Top 10 Holdings %
Top 10 Hldgs %
38.02%
Holding
408
New
159
Increased
53
Reduced
54
Closed
131
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$3.17M |
| 2 |
K
Kellanova
K
|
+$2.19M |
| 3 |
FL
Foot Locker
FL
|
+$2.04M |
| 4 |
General Mills
GIS
|
+$1.95M |
| 5 |
lululemon athletica
LULU
|
+$1.74M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$9.7M |
| 2 |
JPMorgan Chase
JPM
|
+$3.58M |
| 3 |
Gilead Sciences
GILD
|
+$3.38M |
| 4 |
Constellation Brands
STZ
|
+$2.74M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.66% |
| 2 | Consumer Staples | 16.16% |
| 3 | Consumer Discretionary | 9.31% |
| 4 | Communication Services | 3.38% |
| 5 | Materials | 2.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
iShares Biotechnology ETF
IBB
$9.23B
| $207K | 0.27% |
+2,115
| New | +$202K |
|
|
PTLA
77
PUT
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $207K | 0.27% |
+20,000
| New | +$637K |
|
78
CALL
Colgate-Palmolive
CL
$74.4B
| $206K | 0.27% |
59,000
+3,500
| +6% | +$245K |
|
79
Newmont
NEM
$95.8B
| $199K | 0.26% |
+6,044
| New | +$211K |
|
80
PUT
Alnylam Pharmaceuticals
ALNY
$35.7B
| $196K | 0.26% |
13,200
| – | – |
|
|
81
Regeneron Pharmaceuticals
REGN
$70.9B
| $194K | 0.26% |
500
-26,165
| -98% | -$9.7M |
|
82
Sarepta Therapeutics
SRPT
$1.82B
| $189K | 0.25% |
6,376
-22,698
| -78% | -$702K |
|
83
PUT
TransDigm Group
TDG
$67.9B
| $186K | 0.24% |
+20,700
| New | +$4.94M |
|
84
CALL
BioCryst Pharmaceuticals
BCRX
$2.36B
| $179K | 0.24% |
+71,700
| New | +$499K |
|
|
SVVC
85
DELISTED
Firsthand Technology Value Fund, Inc. Common Stock
SVVC
| $177K | 0.23% |
22,238
| – | – |
|
86
CALL
PepsiCo
PEP
$187B
| $165K | 0.22% |
128,000
-37,000
| -22% | -$3.97M |
|
87
CALL
Kimberly-Clark
KMB
$36B
| $160K | 0.21% |
27,000
+24,700
| +1,074% | +$3.11M |
|
|
CLVS
88
PUT
DELISTED
Clovis Oncology, Inc.
CLVS
| $159K | 0.21% |
+16,400
| New | +$997K |
|
89
PUT
AbbVie
ABBV
$450B
| $158K | 0.21% |
82,000
+400
| +0.5% | +$25.1K |
|
90
PUT
Bristol-Myers Squibb
BMY
$124B
| $157K | 0.21% |
+44,600
| New | +$2.45M |
|
|
TSRO
91
CALL
DELISTED
TESARO, Inc.
TSRO
| $155K | 0.2% |
+17,800
| New | +$2.9M |
|
92
CALL
Insmed
INSM
$23.5B
| $152K | 0.2% |
61,500
+38,900
| +172% | +$600K |
|
|
93
Insmed
INSM
$23.5B
| $148K | 0.19% |
+8,475
| New | +$131K |
|
|
CELG
94
PUT
DELISTED
Celgene Corp
CELG
| $146K | 0.19% |
+43,500
| New | +$5.21M |
|
|
DVAX
95
CALL
DELISTED
Dynavax Technologies
DVAX
| $140K | 0.18% |
96,600
+30,700
| +47% | +$148K |
|
96
Monster Beverage
MNST
$95.4B
| $139K | 0.18% |
+6,000
| New | +$134K |
|
97
CALL
Ulta Beauty
ULTA
$20.6B
| $135K | 0.18% |
+10,000
| New | +$2.74M |
|
98
CALL
Clorox
CLX
$11.6B
| $134K | 0.18% |
62,700
+53,700
| +597% | +$6.96M |
|
99
CALL
Hershey
HSY
$34.8B
| $131K | 0.17% |
34,400
+1,900
| +6% | +$204K |
|
100
CALL
Karyopharm Therapeutics
KPTI
$216M
| $130K | 0.17% |
+2,793
| New | +$448K |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q1 2017 Portfolio in Review
As of Q1 2017, FT Options held 408 positions worth $76M, down 13% from $87.1M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
FT Options deployed $112M of net new capital in Q1 2017, opening 159 new positions and adding to 53 existing holdings. Its largest new stake was GW Pharmaceuticals Plc American Depositary Shares: 25,829 shares worth $3.12M.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 45% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $9.7M trimmed.
- FT Options's largest Q1 2017 buy was GW Pharmaceuticals Plc American Depositary Shares: 25,829 shares worth $3.12M.
- FT Options added most to Kellanova in Q1 2017, an estimated $2.19M increase.
- FT Options's biggest Q1 2017 reduction was Regeneron Pharmaceuticals, cutting an estimated $9.7M.
- FT Options fully exited JPMorgan Chase in Q1 2017, selling an estimated $3.58M.
- FT Options's ten largest holdings make up 38% of its $76M portfolio in Q1 2017.
- FT Options opened 159 new positions and closed 131 in Q1 2017.
- FT Options's portfolio value fell 13% quarter-over-quarter to $76M.
Based on FT Options's 13F filing for Q1 2017, filed 12 May 2017.